Literature DB >> 11927941

CD39 is the dominant Langerhans cell-associated ecto-NTPDase: modulatory roles in inflammation and immune responsiveness.

Norikatsu Mizumoto1, Tadashi Kumamoto, Simon C Robson, Jean Sévigny, Hiroyuki Matsue, Keiichi Enjyoji, Akira Takashima.   

Abstract

CD39, the endothelial ecto-nucleoside triphosphate diphosphohydrolase (NTPDase), regulates vascular inflammation and thrombosis by hydrolyzing ATP and ADP. Although ecto-NTPDase activities have been used as a marker of epidermal dendritic cells (DCs) known as Langerhans cells, the identity and function of these activities remain unknown. Here we report that Langerhans cells in CD39-/- mice express no detectable ecto-NTPDase activity. Irritant chemicals triggered rapid ATP and ADP release from keratinocytes and caused exacerbated skin inflammation in CD39-/- mice. Paradoxically, T cell-mediated allergic contact hypersensitivity was severely attenuated in CD39-/- mice. As to mechanisms, T cells increased pericellular ATP concentrations upon activation, and CD39-/- DCs showed ATP unresponsiveness (secondary to P2-receptor desensitization) and impaired antigen-presenting capacity. Our results show opposing outcomes of CD39 deficiency in irritant versus allergic contact dermatitis, reflecting its diverse roles in regulating extracellular nucleotide-mediated signaling in inflammatory responses to environmental insults and DC-T cell communication in antigen presentation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11927941     DOI: 10.1038/nm0402-358

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  127 in total

1.  CD1a and langerin: acting as more than Langerhans cell markers.

Authors:  Norikatsu Mizumoto; Akira Takashima
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

2.  CD4(+)CD25 (+)CD127 (low/-) T cells: a more specific Treg population in human peripheral blood.

Authors:  Ning Yu; Xiaomei Li; Weiya Song; Dongmei Li; Daliang Yu; Xiaofeng Zeng; Mengtao Li; Xiaomei Leng; Xiangpei Li
Journal:  Inflammation       Date:  2012-12       Impact factor: 4.092

3.  IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39.

Authors:  Ivan D Mascanfroni; Ada Yeste; Silvio M Vieira; Evan J Burns; Bonny Patel; Ido Sloma; Yan Wu; Lior Mayo; Rotem Ben-Hamo; Sol Efroni; Vijay K Kuchroo; Simon C Robson; Francisco J Quintana
Journal:  Nat Immunol       Date:  2013-09-01       Impact factor: 25.606

4.  Impaired natriuretic response to high-NaCl diet plus aldosterone infusion in mice overexpressing human CD39, an ectonucleotidase (NTPDase1).

Authors:  Yue Zhang; Simon C Robson; Kaiya L Morris; Kristina M Heiney; Karen M Dwyer; Bellamkonda K Kishore; Carolyn M Ecelbarger
Journal:  Am J Physiol Renal Physiol       Date:  2015-04-15

5.  cAMP/CREB-mediated transcriptional regulation of ectonucleoside triphosphate diphosphohydrolase 1 (CD39) expression.

Authors:  Hui Liao; Matthew C Hyman; Amy E Baek; Keigo Fukase; David J Pinsky
Journal:  J Biol Chem       Date:  2010-02-23       Impact factor: 5.157

Review 6.  The role of purinergic signaling in the liver and in transplantation: effects of extracellular nucleotides on hepatic graft vascular injury, rejection and metabolism.

Authors:  Guido Beldi; Keiichi Enjyoji; Yan Wu; Lindsay Miller; Yara Banz; Xiaofeng Sun; Simon C Robson
Journal:  Front Biosci       Date:  2008-01-01

7.  Structural insight into signal conversion and inactivation by NTPDase2 in purinergic signaling.

Authors:  Matthias Zebisch; Norbert Sträter
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-05       Impact factor: 11.205

8.  Central role of Sp1-regulated CD39 in hypoxia/ischemia protection.

Authors:  Holger K Eltzschig; David Köhler; Tobias Eckle; Tianqing Kong; Simon C Robson; Sean P Colgan
Journal:  Blood       Date:  2008-09-23       Impact factor: 22.113

9.  Attenuated allergic airway inflammation in Cd39 null mice.

Authors:  M Idzko; C K Ayata; T Müller; T Dürk; M Grimm; K Baudiß; R P Vieira; S Cicko; C Boehlke; A Zech; S Sorichter; J Pelletier; J Sévigny; S C Robson
Journal:  Allergy       Date:  2013-03-01       Impact factor: 13.146

10.  Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis.

Authors:  John Stagg; Upulie Divisekera; Nicole McLaughlin; Janelle Sharkey; Sandra Pommey; Delphine Denoyer; Karen M Dwyer; Mark J Smyth
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.